

Frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico

Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Jorge I Gámez-Nava, Mario A Mireles-Ramírez, Laura González-López and Miguel Á Macías-Islas 

Multiple Sclerosis Journal—
Experimental, Translational
and Clinical

January–March 2024, 1–10

DOI: 10.1177/
20552173241231678

© The Author(s), 2024.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract

Background: Between 29% and 67% of neuromyelitis optica spectrum disorder patients have cognitive alterations.

Objective: To assess the frequency of cognitive impairment in patients with neuromyelitis optica spectrum disorder in Mexico using the Brief International Cognitive Assessment for Multiple Sclerosis.

Methods: We evaluated 40 neuromyelitis optica spectrum disorder patients and 40 healthy controls from Mexico.

Results: 28 (70.0%) patients with neuromyelitis optica spectrum disorder had cognitive impairment in two or more cognitive domains. Student's T test showed statistically poor performance by neuromyelitis optica spectrum disorder patients compared to healthy controls on all three neuropsychological test scores. This significant difference was observed on the Symbols Digit Modalities Test ($t=8.875$; $p \leq 0.001$); California Verbal Learning Test-II memory ($t=10.418$; $p \leq 0.001$); and Brief Visuospatial Memory Test Revised ($t=6.123$; $p \leq 0.001$).

Conclusions: This study showed that 70% of neuromyelitis optica spectrum disorder patients exhibited cognitive impairment in two or more cognitive domains. Determining the frequency of cognitive impairment will guide the decision of Neuropsychologists in planning cognitive rehabilitation across various domains.

Keywords: Cognitive impairment, Brief International Cognitive Assessment for Multiple Sclerosis, processing speed, verbal memory, visuospatial memory, neuromyelitis optica spectrum disorders

Date received: 7 August 2023; accepted: 24 January 2024

Introduction

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system that primarily affects the optic nerve and spinal cord, usually with a severe and relapsing course.^{1,2} NMOSD onset is at about 39 years of age and is more prevalent among women.³ In 2022, a prevalence of 0.71/100,000 (95% CI 0.55–0.92) was estimated in western Mexico.⁴

Patients with NMOSD often experience a higher number of deficits, such as physical disability, depression, anxiety, cognitive impairment (CI), pain, and fatigue that reduces the quality of life.^{5–13}

Investigations performed in patients with NMOSD have allowed the establishment of the frequency of cognitive alterations.^{6,14,15} Cognitive deficits are

present in 29%–67% of NMOSD patients.^{16–18} Studies conducted in this population have identified the presence of alterations in attention, memory, processing speed, verbal fluency, verbal memory, and executive function.^{19–21} This characterization of cognitive alterations has been made possible by the existence of neuropsychological batteries designed for cognitive assessment.

In general, numerous cognitive batteries and neuropsychological tests have been developed and validated in different countries for assessing cognitive functions in patients with multiple sclerosis (MS).²² However, there is no expert consensus on which neuropsychological batteries are better to assess cognitive function in NMOSD patients.^{19,23} One of the most widely used batteries to facilitate the assessment of cognitive function in MS is the Brief International

Correspondence to:
Miguel Á Macías-Islas,
Departamento de
Neurociencias, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, 44340
Guadalajara, Jalisco, México.
[miguelangelmacias@
hotmail.com](mailto:miguelangelmacias@hotmail.com)

**Edgar R Valdivia-
Tangarife**,
Departamento de
Neurociencias, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, Guadalajara,
México

Fernando Cortés-Enríquez,
Departamento de Neurología,
Hospital General, No 14 del
Instituto Mexicano del
Seguro Social, Guadalajara,
México



Alejandra Morlett-Paredes,
Departamento de
Neurociencias, Universidad
de California San Diego, La
Jolla, CA, USA

**Teresita Villaseñor-
Cabrera,**
Departamento de
Neurociencias, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, Guadalajara,
México
O.P.D Hospital Civil Fray
Antonio Alcalde,
Guadalajara, México

Jorge I Gámez-Nava,
Programa de Doctorado en
Farmacología, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, Guadalajara,
México

Mario A Mireles-Ramírez,
Departamento de Neurología,
Unidad de Alta Especialidad
Médica, Centro Médico
Nacional de Occidente,
Instituto Mexicano del
Seguro Social, Guadalajara,
México

Laura González-López,
Programa de Doctorado en
Farmacología, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, Guadalajara,
México

Miguel Á Macías-Islas,
Departamento de
Neurociencias, Centro
Universitario de Ciencias de
la Salud, Universidad de
Guadalajara, Guadalajara,
México

Cognitive Assessment for MS (BICAMS).²⁴ This clinical tool assesses processing speed, verbal memory, and visuospatial memory.²⁵ Several studies have examined CI in NMOSD patients. For instance, Salama et al.²⁶ conducted a transversal study that included 20 NMOSD patients and 18 healthy controls (HCs). This study identified a frequency of CI in 75% of patients with NMOSD, with deficits mostly seen in processing speed and verbal memory domains.²⁶ In 2023, Lopes et al.²⁷ conducted a retrospective study that included 19 NMOSD patients, 27 MS patients, and 18 HCs. The study identified that patients with NMOSD had significantly lower cognitive performance than the HCs group.²⁷

Despite the increasing number of investigations on NMOSD populations, there is a lack of research regarding cognitive alterations in patients with NMOSD. At the time of publication of this manuscript, there were no studies identifying the prevalence of CI in NMOSD populations from Mexico. Therefore, the objective of this study was to evaluate the frequency of CI in patients with NMOSD in Mexico using the BICAMS.

Methods

Participants

The present study included 80 Mexican participants who were divided into two groups. The first group consisted of 40 Mexican adults diagnosed with NMOSD. The Second group consisted of 40 HCs. These 40 HCs were selected to match the NMOSD sample on demographic characteristics. The groups did not differ with regard to age (NMOSD group = 39.50 ± 10.61 years; HCs group = 39.98 ± 10.01 years, $p = 0.837$), years of education (NMOSD group = 6.08 ± 3.40 years; HCs group = 6.73 ± 3.50 years, $p = 0.403$), and sex (NMOSD group = 87.5% female; HCs group = 80.0% female, $p = 0.56$).

The inclusion criteria for patients diagnosed with NMOSD were as follows: (a) A diagnosis of NMOSD according to the 2015 international consensus diagnostic criteria for NMOSDs.¹³ All medical records of patients with NMOSD were reviewed by 3 neurologist researchers; (b) a signed informed consent form; (c) an age between 18 and 60 years at the time of the cognitive assessment; (d) do not have visual (must be better than 20/200 in at least one eye) or auditory limitations to performed the tests; (e) dominant hand strength had to be 4+/5 or more in the modified Medical Research Council (mMRC) scale. This information was corroborated in the neurology consultations; and (f) not having an intellectual disability. We used the Wechsler Adult Intelligence Scale (WAIS-IV), and it was determined

by neuropsychologist researchers. The exclusion criteria were as follows: (a) History of a neurological or psychiatric diagnosis; (b) substance and/or alcohol consumption; (c) a relapse within the last 30 days of cognitive assessment; and (d) treatment with corticosteroids within the last 30 days.

The inclusion criteria for HCs were as follows: (a) Being born and currently living in Mexico; (b) speaking Spanish as their native language; (c) being between 18 and 60 years at the time of the cognitive evaluation; (d) having completed at least one year of formal education; and (e) being able to read and write. The exclusion criteria for HCs were (a) having a history of neurological alterations, developmental disorders, learning disabilities, and psychiatric disorders; (b) having a score ≥ 23 on the mini-mental state examination (MMSE) ($MMSE = 28.65 \pm 1.31$)²⁸; (c) having a score ≥ 90 on the Barthel Index (Mahoney & Barthel., 1965); (d) having a score ≤ 4 on the Patients Health Questionnaire-9 (PHQ-9) ($PHQ-9 = 1.42 \pm 0.71$)²⁹; and (e) having visual, auditory, or sensory problems.

Instruments

The Brief International Cognitive Assessment for MS (BICAMS) was developed by expert neurologists and neuropsychologists as a battery for assessing cognitive function in patients with MS.³⁰ This instrument consists of three different tests:

1. The symbols digit modalities test (SDMT). The SDMT involves a key two rows, where the upper row contains a series of nine abstract geometric symbols and the lower row contains corresponding number (1–9). Participants are instructed to verbally associate each symbol with its corresponding number as quickly as possible within a 90-s time frame. The score for this test is determined by the number of correct substitutions completed within the given time limit, with a maximum score of 110.^{25,31,32}
2. The California Verbal Learning Test (CVLT-II). The CVLT-II requires the examiner to read a list of 16 words in five trials. Participants are then asked to recall as many words as they can remember (in any order) a list given by the psychometrist of the study. The score for this test is calculated based on the total number of words correctly recalled across the five trials.³³
3. The Brief Visuospatial Memory Test Revised (BVMT-R). In the BVMT-R, participants are shown a sheet of paper containing six geometric designs for a duration of 10 s. After the stimulus is removed, participants are given paper and pencil to draw the geometric designs from

memory. Scores are determined by summing the scores from three trials (each drawing received a score of 0–2 points).³⁴

To measure CI we established criteria based on the clinical experience of the neuropsychologists participating in the study (EVT; AMP; TVC); and a review of the literature.^{14,17,35,36} The criteria for CI include (a) Patients with scores two or more standard deviations below the mean compared to HCs and (b) patients with scores below the mean by two or more standard deviations in two or more cognitive domains were also classified as having CI.

Statistical analysis

We used the statistical software R version 4.0.3 (R console Team 2020) to perform the statistical analysis. Kolmogorov-Smirnov and Levenés tests were used to evaluate normal distribution and homoscedasticity in the quantitative variables in both groups; most of the scores did meet the assumptions of normality and homoscedasticity. Qualitative variables were described as frequencies (%) and quantitative variables were described as means $\pm$ standard deviation. For univariate analysis we used chi-square test or Fisher's exact test (when required). For the comparison of means $\pm$ standard deviation of quantitative variables between NMOSD patients and HCs, student's test was performed.

All composite scores were created using Stouffer's Z method.^{37,38} Student's *t*-test was used to compare groups (NMOSD and HCs) according to different domains (processing speed, learning and verbal memory, and visuospatial memory).

Results

Clinical characteristics of NMOSD patients

We included 40 patients with an NMOSD diagnosis. Of those 40, 19 (47.5%) patients had myelitis, 14 (35.0%) patients had optic neuritis, and 7 (17.5%) had area postrema syndrome. The average time from diagnosis to cognitive assessment was 52 months, range (12–139). AQP4-IgG antibody was tested in 30 of 40 patients, with 27 of them (67.5%) having a positive result, while 10 (25%) patients had an unknown status (data not shown). At the time of the cognitive assessment a percentage of NMOSD patients were taking azathioprine ($n = 10$), mycophenolate mofetil ($n = 3$), and rituximab ($n = 27$).

Cognitive function

Student's test showed statistically poor performance by NMOSD patients compared to HCs on all three neuropsychological test scores. This significant difference was observed on the SDMT ($t = 8.875$;

Table 1. Comparison between patients with NMOSD vs HCs on neuropsychological test scores.

BICAMS	NMOSD ($n = 40$)		HCs ($n = 40$)		<i>t</i>	<i>p</i> -value
	Mean	SD	Mean	SD		
SDMT	40.33	11.18	57.65	5.51	8.875	<0.001
CVLT-II	43.45	6.46	55.93	3.93	10.418	<0.001
BVMT-R	18.90	5.40	24.93	3.09	6.123	<0.001
Comparison between groups was made using Student <i>t</i> -test. BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; NMOSD: neuromyelitis optica spectrum disorders; HCs: healthy control; SDMT: Symbols Digit Modalities Test; CVLT-II: California Verbal Learning Test-II; BVMT-R: Brief Visuospatial Memory Test Revised; SD: standard deviation.						

Table 2. Average performance between patients with NMOSD vs HCs.

Cognitive domains	NMOSD patients ($n = 40$)		HC ($n = 40$)		<i>t</i>	<i>p</i> -value
	Mean Z-scores	SD	Mean Z-scores	SD		
Processing speed	−1.02	0.88	0.51	0.56	10.531	<0.001
Verbal memory	−0.99	0.69	0.49	0.71	11.952	<0.001
Visuospatial memory	−0.79	−0.76	0.39	0.85	6.662	<0.001
Comparison between means of z-scores were made using Student <i>t</i> -test. NMOSD: neuromyelitis optica spectrum disorders; HCs: healthy control; SD: standard deviation.						




Figure 1. Processing speed.




Figure 2. Learning and memory.

$p \leq 0.001$); CVLT-II memory ($t = 10.418$; $p \leq 0.001$); and BVM-T-R ($t = 6.123$; $p \leq 0.001$) (Table 1).

In Table 2, we show a significant difference between the groups in all cognitive domains. Processing speed ($t = 10.531$; $p \leq 0.001$); learning and memory ($t = 11.952$; $p \leq 0.001$); and visuospatial memory ($t = 6.662$; $p \leq 0.001$); where NMOSD patients presented

worse means Z-scores in each domain compared to HCs subjects (Figures 1–3).

We compared CI in NMOSD patients and those without CI. NMOSD patients with CI performed lower in the SDMT ($t = 3.191$; $p = 0.003$); CVLT-II memory ($t = 2.473$; $p = 0.018$); and BVM-T-R ($t = 3.590$; $p = 0.001$) (Table 3).




Figure 3. Visuospatial memory.

Table 3. Comparison of cognitive functions between NMOSD patients with and without CI.

BICAMS	NMOSD patients with CI (<i>n</i> = 28)		NMOSD patients without CI (<i>n</i> = 12)		<i>t</i>	<i>p</i> -value
	Mean	SD	Mean	SD		
SDMT	37.0	9.56	48.08	11.20	3.191	0.003
CVLT-II	41.89	5.41	47.08	7.47	2.473	0.018
BVMT-R	17.14	4.64	23.00	4.93	3.590	0.001

Comparison between groups were made using Student *t*-test. BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; NMOSD: neuromyelitis optica spectrum disorders; HC: healthy control; CI: cognitive impairment; SDMT: Symbols Digit Modalities Test; CVLT-II: California Verbal Learning Test-II; BVMT-R: Brief Visuospatial Memory Test Revised; SD: standard deviation.

Discussion

The objective of this study was to determine the prevalence of CI in patients with NMOSD in Mexico. The results revealed the following: (a) 70% of NMOSD patients exhibited CI in two or more cognitive domains. (b) 80% of the patients had impairment on verbal memory. (c) 77% of the patients had CI in processing speed (d) and 47% in visuospatial memory.

Several previous studies have assessed and compared CI in MS and NMOSD patients.^{14,17,18,20,39–41} In Latin America (LATAM) there is a lack of research and information regarding the prevalence of CI in NMOSD patients. To date, only one study has been conducted in LATAM (Argentina; 39) that included patients diagnosed NMOSD (*n* = 14), MS (*n* = 14),

and HCs (*n* = 14). They found that 57% of NMOSD patients had abnormal performance in at least two cognitive tests. In Mexico, this is the first study evaluating the prevalence of CI in NMOSD patients, revealing that 80% of patients diagnosed with NMOSD had abnormal performance in at least two cognitive tests.

On the other hand, it is important to highlight some methodological differences between the present study and previous research. For instance: (a) the sample size of the groups is different, especially in the NMOSD group, as we included 40 NMOSD patients, while a study conducted in Egypt by Salama et al.,²⁶ included 20 NMOSD patients and found that 75% of them had CI in two or more cognitive domains (Information processing speed and

Table 4. Cognitive performance in previous studies that include NMOSD patients.

Reference	Sample size	Cognitive test	Cognitive impairment
Blanc et al. ¹⁴	30 NMOSD 30 MS 30 HCs	The BCcogSEP	30% of NMOSD patients had abnormal long-term memory impairment. 3.3% of NMOSD had abnormal short-term memory. 20% of NMOSD patients had abnormal information-processing speed. 26.7% of NMOSD patients had executive function dysfunction. 13.3% of NMOSD patients had language dysfunctions.
He et al. ⁷	22 NMOSD 22 Depression patients 22 HCs	CVLT Backward DST Clock Drawing Task (CLOX) SDMT PASAT	The patients with NMOSD had cognitive deficits in memory, information processing speed, and attention.
Blanc et al. ¹⁵	28 NMOSD 28 HCs	The BCcogSEP	54.4% of NMOSD patients had cognitive impairment with more than four subtests of the BCcogSEP inferior to the 5th percentile. 30% of NMOSD patients had an impairment in PASAT 3 s, the DSST, the BCcog-SRT, and the digit span.
Saji et al. ⁴³	14 NMOSD 17 MS	BRBN	57% of NMOSD patients had impaired performance (inferior to the 5th percentile) on at least 3 cognitive tests.
Vanotti et al. ¹⁸	14 NMOSD 14MS 14 HCs	BRBN	57% of NMOSD patients had abnormal performance in at least two cognitive tests.
Kawahara et al. ²⁰	35 MS 10 NMOSD 55 HCs	MMSE HSR FAB GDS	NMOSD patients did not differ from the normal control group in any of the three cognitive assessments.
Wang et al. ⁴⁰	50 NMOSD 50 HCs	CVLT-II PASAT The symbol digit technique The Controlled Oral Word Associated Test The Wisconsin Card Storing Test The COWAT	NMOSD patients had impairments in memory, information processing speed, and verbal fluency.
Zhang et al. ³⁶	36 NMOSD 30 HCs	MMSE MoCA The MACFIMS	NMOSD patients were significantly impaired in the paced auditory serial addition task, the SDMT, the CVLT, the brief visuospatial

(continued)

Table 4. Continued.

Reference	Sample size	Cognitive test	Cognitive impairment
Kim et al. ¹⁶	82 NMOSD 58 MS 45 HCs	SVLT The Korean version of the HVLIT-R RCFT The COWAT The SDMT PASAT Digit Span The Stroop Color and Word tests PHQ-9 BFI	memory test-revised and semantic fluency. Cognitive impairment was observed in 29% of NMOSD patients.
Moore et al. ¹⁷	42 NMOSD 42 MS 42 HCs	CVLT WAIS-IV SDMT Delis–Kaplan Executive Functioning System The Mini International Neuropsychiatric Interview HADS	Cognitive impairment was observed in 67% of NMOSD patients.
Kim et al. ³⁹	73 NMOSD 44 HCs	Neuropsychological battery SVLT The Korean version of the HVLIT-R RCFT The COWAT The SDMT PASAT Digit Span The Stroop Color and Word tests PHQ-9 BFI	Cognitive impairment was observed in 32% of patients.
Fujimori et al. ³⁵	12 NMOSD 14 MS	Brief Cognitive Screening (The Japan version of the Rao Brief Repeatable Neuropsychological Battery-BRBN) WAIS-II WMS-R	41.7% of NMOSD patients were assessment as cognitively impairment by BRBN.
Salama et al. ²⁶	20 NMOSD 18 HCs	MoCA BICAMS	75% of NMOSD patients had cognitive impairment in two or more cognitive domains.
Yabalak et al. ⁴¹	22 NMOSD	BRBN BDI ACE-R	45.5% of NMOSD patients had cognitive impairment.
Lopez et al. ⁴²	41 NMOSD	BRBN	34% of NMOSD patients had cognitive impairment.
Lopes et al. ²⁷	19 NMOSD	BICAMS	NMOSD patients had a significant lower cognitive performance when

(continued)

Table 4. Continued.

Reference	Sample size	Cognitive test	Cognitive impairment
	27 MS 18 HCs		compared to HC mainly in information processing speed, concentration, language processing, and executive functions
Present study	40 NMOSD 40 HCs	BICAMS	70% of NMOSD patients had cognitive impairment
BCCogSEP: Batterie Courte d'évaluation Cognitive destinee aux patients souffrant de Sclerose en Plaques; NMOSD: neuromyelitis optica spectrum disorders; HCs: healthy control; BICAMS: Brief International Cognitive Assessment for Multiple Sclerosis; MMSE: mini-mental state examination; PHQ-9: Patient Health Questionnaire-9; SDMT: Symbols Digit Modalities Test; CVLT: California Verbal Learning Test; BRBN: Brief Repeatable Battery of Neuropsychological Test; DST: Digit Span Test; PASAT: Paced Auditory Serial Addition Test; HSR: Hasegawa dementia scale revised; FAB: Frontal assessment battery; COWAT: Controlled Oral Word Association Test; MoCA: Montreal Cognitive Assessment; MACFIMS: Minimal Assessment of Cognitive Function in Multiple Sclerosis; SVLT: Seoul Verbal Learning Test; HVLT-R: Hopkins Verbal Learning Test-Revised; RCFT: Rey Complex Figure Test; BFI: Brief Fatigue Inventory; WAIS: Wechsler Adult Intelligence Scale; HADS: Hospital Anxiety and Depression Scale; WMS-R: Wechsler Memory Scale-Revised; BDI: Beck Depression Inventory; ACE-R: Addenbrooke cognitive evaluation-revised.			

memory). In Turkey, a retrospective study conducted by Yabalak et al.,⁴¹ included 22 patients and reported that 45.5% of NMOSD patients had a CI (Memory, attention, and processing speed). In Japan, a study conducted by Fujimori et al.³⁵ included 12 patients with NMOSD and showed that 41.7% had CI (Perceptual organization, working memory, and processing speed). In Spain, Lopez et al.⁴² included 41 NMOSD patients and showed that 34% had a CI (visual memory and attention). A recent paper by Portugal, Lopes et al.²⁷ included 19 NMOSD patients and reported significant CI (compared to HCs) in the areas of processing speed, concentration, language processing, and executive function. (b) Additionally, the number of cognitive domains evaluated by the neuropsychological test batteries varied from study to study. For Example, some studies assessed CI using the Brief Repeatable Battery of Neuropsychological Test,^{18,35,41–43} while others used the BICAMS to assess.^{26,27}

Currently, the majority of instruments used in NMOSD patients have not been standardized and validated for use in these populations (Table 4). In the present study, the BICAMS was used to assess the primary cognitive domains affected in patients with NMOSD. Our results indicated that patients with NMOSD had significantly lower scores compared to HCs. In summary, the findings of the present study validate the utility of the BICAMS battery in differentiating between HCs and those with NMOSD diagnoses. However, the significance of this study lies in the fact that cognitive assessment was conducted on

Mexican patients diagnosed with NMOSD to determine the prevalence of CI.

Study limitations

Results from the current study should be interpreted in the context of limitations. *First*, this study focused on evaluating cognitive function at a single point in time. Although our objective was to assess the cognitive function of Mexican individuals with NMOSD. We were unable to gather information regarding changes in cognitive function over time. Future longitudinal cohort studies should address this limitation to determine changes in the cognitive function. *Second*, our patients were exclusively from a tertiary-care center. Patients from tertiary-care centers typically exhibit more aggressive disease, higher hospitalization rates, requirements for immunosuppressive drugs, and comorbidities compared to NMOSD patients at secondary-care centers. Future studies should include NMOSD patients from secondary-care centers for comparison. *Third*, the patients in this study were recruited from a public hospital (Centro Medico Nacional de Occidente, in Guadalajara, Mexico). Therefore, the finding of this study may not be directly applicable to NMOSD patients treated in private settings, as the quality of care can vary, potentially influencing the overall impact of NMOSD on cognition.

Procedure

All participants gave their informed consent before being included in the study. This study was designed following the principles of the 64th Declaration of Helsinki (last revision Fortaleza, Brazil 2013). The

Research and Ethics Committee of the Centro Medico Nacional de Occidente at the Instituto Mexicano del Seguro Social, in Guadalajara, Mexico, approved this study (code of approval: R-2019-1301-023). The medical records of patients admitted to the neurology unit with an NMOSD diagnosis were reviewed to select patients who met the inclusion criteria. Patients meeting the inclusion criteria were contacted and invited to participate, and those who accepted were contacted to schedule the evaluation. After the informed consent was given and signed, all participants completed the BICAMS battery to measure cognitive function.

Conclusion

This study observed that 70% of NMOSD patients had CI. In our sample, the cognitive domains most affected were verbal memory and processing speed. Whereas visuospatial memory impairment was observed in less than 50% of NMOSD patients. The utilization of BICAMS can offer valuable insights into CI in NMOSD patients, providing Neuropsychologist working with NMOSD patients from Mexico with information that can be utilized for planning cognitive rehabilitation across various domains.

Highlights

- 70% of NMOSD patients had CI.
- The most affected CI was verbal memory.
- NMOSD patients obtained lower scores in all cognitive functions.
- Prompt recognition of CI is paramount to cognitive rehabilitation.

Author contribution

Conceptualization was done by Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, and Miguel A Macías-Islas. Data curation was done by Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Mario A. Mireles-Ramírez, and Laura González-López. Formal analysis was done by Edgar R. Valdivia-Tangarife and Jorge I. Gámez-Nava. Investigation was done by Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, and Laura González-López. Methodology was designed by Edgar R Valdivia-Tangarife, Jorge I. Gámez-Nava, and Laura González-López. Supervision was done by Miguel A Macías-Islas, Fernando Cortés-Enríquez, and Jorge I Gámez-Nava. Writing—original draft was done by Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Gámez-Nava, Mario Alberto, Mireles-Ramírez, and Miguel Ángel Macías-Islas. Writing—review & editing was done by Edgar R Valdivia-Tangarife, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Teresita Villaseñor-Cabrera, Jorge I. Gámez-Nava, Mario A Mireles-Ramírez, Laura González-López, and Miguel Ángel Macías-Islas. All authors read and approved the final manuscript.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

The Research and Ethics Committee of the Centro Medico Nacional de Occidente at the Instituto Mexicano del Seguro Social, in Guadalajara, Mexico, approved this study (code of approval: R-2019-1301-023).

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Informed consent

All participants gave their informed consent before being included in the study.

ORCID iD

Miguel Á Macías-Islas  <https://orcid.org/0000-0002-0936-7525>

References

1. Prasad S and Chen J. What you need to know about AQP4, MOG, and NMOSD. *Semin Neurol* 2019; 39: 718–731.
2. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology* 2015; 85: 177–189.
3. Borisow N, Kleiter I, Gahlen A, et al. Nemos (Neuromyelitis Optica Study Group). Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. *Mult Scler J* 2017; 23: 1092–1103.
4. Mireles-Ramírez MA, Cortes-Enríquez F, Valdivia-Tangarife ER, et al. Neuromyelitis optica spectrum disorder in western Mexico. *Mult Scler Relat Disord* 2022; 61: 103733.
5. Asseger S, Schmidt F, Chien C, et al. Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders. *Mult Scler J Exp Transl Clin* 2018; 4: 2055217318796684.
6. Chanson JB, Zephir H, Collongues N, et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. *Eur J Neurol* 2011; 18: 836–841.
7. He D, Chen X, Zhao D, et al. Cognitive function, depression, fatigue, and activities of daily living in patients with neuromyelitis optica after acute relapse. *Int J Neurosci* 2011; 121: 677–683.
8. Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, et al. The immunology of neuromyelitis optica—current knowledge, clinical implications, controversies and future perspectives. *Int J Mol Sci* 2016; 17: 73.
9. Jiao Y, Fryer JP, Lennon VA, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. *Neurology* 2013; 81: 1197–1204.
10. Mutch K, Methley A, Moore P, et al. Life on hold: the experience of living with neuromyelitis optica. *Disabil Rehabil* 2014; 36: 1100–1107.

11. Nakazawa K, Noda T, Ichikura K, et al. Resilience and depression/anxiety symptoms in multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler Relat Disord* 2018; 25: 309–315.
12. Valdivia-Tangarife ER, Gamez-Nava JI, Cortés-Enríquez F, et al. Risk factors associated with permanent disability in neuromyelitis optica spectrum disorders. *Mult Scler Relat Disord* 2022; 68: 104114.
13. Wingerchuk DM, Hogancamp WF, O'Brien PC, et al. The clinical course of neuromyelitis optica (devic's syndrome). *Neurology* 1999; 53: 1107–1107.
14. Blanc F, Zéphir H, Lebrun C, et al. Cognitive functions in neuromyelitis optica. *Arch Neurol* 2008; 65: 84–88.
15. Blanc F, Noblet V, Jung B, et al. White matter atrophy and cognitive dysfunctions in neuromyelitis optica. *PLoS One* 2012; 7: e33878.
16. Kim SH, Kwak K, Jeong IH, et al. Cognitive impairment differs between neuromyelitis optica spectrum disorder and multiple sclerosis. *Multiple Sclerosis J* 2016; 22: 1850–1858.
17. Moore P, Methley A, Pollard C, et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. *J Neurol Sci* 2016; 360: –9.
18. Vanotti S, Cores EV, Eizaguirre B, et al. Cognitive performance of neuromyelitis optica patients: comparison with multiple sclerosis. *Arq Neuropsiquiatr* 2013; 71: 357–361.
19. Czarnecka D, Oset M, Karlińska I, et al. Cognitive impairment in NMOSD—more questions than answers. *Brain Behav* 2020; 10: e01842.
20. Kawahara Y, Ikeda M, Deguchi K, et al. Cognitive and affective assessments of multiple sclerosis (MS) and neuromyelitis optica (NMO) patients utilizing computerized touch panel-type screening tests. *Intern Med* 2014; 53: 2281–2290.
21. Moghadas AN, Mirmosayyeb O, Mohammadi A, et al. The prevalence of cognitive impairment in patients with neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. *Mult Scler Relat Disord* 2021; 49: 102757.
22. Ezegebe C, Zarghami A, van der Mei I, et al. Instruments measuring change in cognitive function in multiple sclerosis: a systematic review. *Brain Behav* 2023; 13: e3009.
23. Langdon D, Amato M, Boringa J, et al. The brief international cognitive assessment for multiple sclerosis (BICAMS): first consensus steps towards a brief universal cognitive assessment for MS. *Neurology*; 76: A479–A479.
24. Langdon DW, Amato MP, Boringa J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). *Multiple Sclerosis J* 2012; 18: 891–898.
25. Benedict RH, DeLuca J, Phillips G, et al. *Multiple Sclerosis J* 2017; 23: 721–733.
26. Salama S, Marouf H, Reda MI, et al. Cognitive functions in Egyptian neuromyelitis optica spectrum disorder. *Clin Neurol Neurosurg* 2020; 189: 105621.
27. Lopes C, Sousa C, Fraga A, et al. Cognitive impairment in neuromyelitis Optica Spectrum disorder: a retrospective study using the brief international cognitive assessment for multiple sclerosis (BICAMS). *Appl Neuropsychol: Adult* 2023; 1–7.
28. Folstein MF, Folstein SE and McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189–198.
29. Kroenke K, Spitzer RL and Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* 2001; 16: 606–613.
30. Benedict RH, Amato MP, Boringa J, et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation. *BMC Neurol* 2012; 12: 1–7.
31. Smith A. *Symbol Digit Modalities Test (SDMT)*. Manual (revised). Los Angeles: Western Psychological Services, 1982.
32. Vanotti S, Smerbeck A, Eizaguirre MB, et al. BICAMS In the Argentine population: relationship with clinical and sociodemographic variables. *Appl Neuropsychol: Adult* 2018; 25: 424–433.
33. Delis DC, Kramer JH, Kaplan E, et al. *California verbal learning test*. 2nd ed. San Antonio, TX, USA: Psychological Corporation, 2000.
34. Benedict R. *The brief visuospatial memory test revised (BVM-T-R)*. Lutz, FL, USA: Psychological Assessment Resources Inc, 1997.
35. Fujimori J, Nakashima I, Baba T, et al. Cognitive impairment in neuromyelitis optica spectrum disorders: A comparison of the wechsler adult intelligence scale-III and the wechsler memory scale revised with the rao brief repeatable neuropsychological battery. *Neurologicalsci* 2017; 9: –7.
36. Zhang N, Li YJ, Fu Y, et al. Cognitive impairment in Chinese neuromyelitis optica. *Multiple Sclerosis J* 2015; 21: 1839–1846.
37. Ledesma R, Macbeth G and De Kohan NC. Tamaño del efecto: revisión teórica y aplicaciones con el sistema estadístico ViSta. *Revista Latinoamericana de Psicología* 2008; 40: 425–439.
38. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. *J Evol Biol* 2005; 18: 1368–1373.
39. Kim SH, Park EY, Park B, et al. Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. *Sci Rep* 2017; 7: 9180.
40. Wang Q, Zhang N, Qin W, et al. Gray matter volume reduction is associated with cognitive impairment in neuromyelitis optica. *Am J Neuroradiol* 2015; 36: 1822–1829.
41. Yabalak A, Altunrende B and Demir GA. Cognitive impairment in neuromyelitis optica. *Arch Neuropsychiatry* 2021; 58: 00.
42. Lopez-Soley E, Meca-Lallana JE, Llufríu S, et al. Cognitive performance and health-related quality of life in patients with neuromyelitis Optica Spectrum disorder. *J Pers Med* 2022; 12: 43.
43. Saji E, Arakawa M, Yanagawa K, et al. Cognitive impairment and cortical degeneration in neuromyelitis optica. *Ann Neurol* 2013; 73: 65–76.